SUMMARY Background
Real-life long-term data on infliximab treatment in ulcerative colitis are limited.
Aim
To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined.
Methods
A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant.
Results
Steroid-free clinical remission was achieved by 123/250 patients (49.2%) at 12 months and in 126/250 patients at a median follow-up of 2.9 years (50.4%). Primary response at 3 months was achieved by 190/250 (76.0%) patients and associated with a high probability of response 168/190 (88.4%) at 12 months and 143/190 (75.3%) at follow-up. Long-term rate of colectomy in primary responders was 6/190 (3.2%) at 12 months and 27/190 (14.2%) at last followup. Failure to achieve response at 3 months was associated with a high risk of subsequent colectomy, 29/60 (48.3%) at 12 months and 41/60 (68.3%) at follow-up. Response at 12 months was associated with a low risk of subsequent colectomy, 14/181 (7.7%) compared with non-response 19/34 (55.9%) (P < 0.0001). Non-response at 3 months was an independent predictor of subsequent colectomy (HR = 9.40, 95% CI = 5.10-17.35, P < 0.001). Concomitant azathioprine therapy did not influence outcome in terms of colectomy.
INTRODUCTION
Ulcerative colitis is a chronic relapsing disease of elusive aetiology causing continuous colonic mucosal inflammation. Infliximab, a monoclonal chimeric antibody to tumour necrosis factor a, has been shown to be effective as rescue therapy in patients with an acute severe attack of ulcerative colitis, reducing the risk of colectomy both short and long term. [1] [2] [3] [4] The ACT 1 and 2 studies showed efficacy of infliximab in patients with chronic active ulcerative colitis. 5 However, the results from randomised trials do not necessarily reflect the efficacy of a drug in clinical practice and seldom address possible long-term benefit. 6 Furthermore, ulcerative colitis displays variations in course and activity, which might influence treatment outcomes, especially long term. An acute flare followed by a period of remission is the most common pattern in ulcerative colitis, while chronic continuous inflammation is less common. 7 Previous real-life studies on infliximab in ulcerative colitis have not separated patients with an acute severe attack of ulcerative colitis from patients with chronic active disease, with the exception of a Swedish multicentre study on 211 patients with an acute severe attack of ulcerative colitis. 8 Thus, information regarding infliximab treatment outcomes in different subpopulations of ulcerative colitis is scarce. Predictors of long-term outcome are sparse, as most previous studies have been limited by a short follow-up. Combination treatment with infliximab and azathioprine has been shown to be associated with a favourable outcome in thiopurine naive patients with a steroid-dependent ulcerative colitis both at 12 months and long term. [9] [10] [11] Disease duration >2 years has been shown to predict a more favourable outcome compared to shorter duration. 12 Clinical response and mucosal healing are independent predictors of a favourable long-term outcome in patients with refractory ulcerative colitis. 13 The primary aim of this multicentre study was to explore the long-term efficacy and safety of infliximab treatment in a large and well-defined group of patients with chronic active ulcerative colitis. More specifically, we wanted to assess the response and remission at 12 months and after long-term follow-up as well as the colectomy rate. Furthermore, we attempted to identify predictors for long-term response and colectomy.
MATERIALS AND METHODS
This was a retrospective Swedish multicentre study, conducted in collaboration with the Swedish Organization for the study of Inflammatory Bowel disease (SOIBD) and approved by the Regional Research Ethics committee, Lund. Data were captured from 15 Swedish IBD centres, including seven academic and eight district hospitals. Patients with ulcerative colitis, treated with infliximab, were identified through local registers of IBD patients receiving biological treatment. The patients included started infliximab treatment between January 2004 and December 2011. Data regarding age, gender, disease duration, extent, body weight, laboratory values data [haemoglobin, albumin, C-reactive protein (CRP), white blood cell count and F-calprotectin] were collected retrospectively at baseline using a study-specific case record form. Data regarding previous and concomitant medication were assessed including 5-aminosalicylic acid, corticosteroids and immunomodulators, duration of treatment with immunomodulators as well as reason for discontinuation. The diagnosis of ulcerative colitis was based on established conventional diagnostic criteria. 14 All patients had a documented colonoscopy and infections were excluded. Extent of disease was defined according to the Montreal classification. 15 An interval of more than 4 months between two infusions of infliximab was considered as a treatment discontinuation. At each discontinuation of infliximab, data regarding reason for discontinuation and concurrent treatment with corticosteroids or azathioprine/mercaptopurine were captured. Safety data regarding severe adverse events were documented. In addition to the time and reason for colectomy, complications occurring within 1 month after surgery were registered. All patients were followed for at least 12 months, until colectomy or shift to another biologic.
Inclusion and exclusion criteria
Inclusion criteria were as follows: (i) ambulatory infliximab treatment, (ii) age ≥18 years at first infliximab infusion, (iii) steroid dependency, defined as ≥8 weeks of oral treatment with ≥10 mg/day prednisolone during the last 12 weeks or at least 3 months of ≥10 mg/day prednisolone during the last 6 months, and/or (iv) intolerance/non-response to immunomodulators (azathioprine, mercaptopurine and methotrexate), and with no imminent risk for colectomy. Patients with Crohn's disease or any previous surgery involving the colon were excluded.
Outcome measures
The following outcome measures were studied: (i) clinical response at 3 and 12 months and at follow-up, (ii) clinical remission at 12 months and at follow-up and (iii) need for colectomy. Clinical remission was defined as well-being and the absence of diarrhoea, blood and abdominal pain. Response was defined as a marked clinical improvement compared to baseline (less diarrhoea, bloody stools and abdominal pain), all parameters as assessed by the treating physician. The response to induction treatment at 3 months was defined as primary response.
Statistics
Categorical variables are presented as frequencies and differences between groups were compared using the chi-square test when appropriate. Continuous variables are presented as median and interquartile range (IQR 
RESULTS

Baseline Characteristics
Totally, 250 patients were included; baseline demographics and clinical characteristics are presented in Table 1 treatment with infliximab due to acute severe ulcerative colitis, followed by discontinuation of IFX for at least 4 months prior to inclusion. The median observation time was 2.9 years (IQR 1.6-4.8).
In total, 3474 IFX doses were administered to 250 patients. Of those, 191 (76%) patients finished their first course of infliximab treatment with a median of four doses (IQR 3-10), and of those, 48/191 patients were treated with a second course of infliximab with a median of 6 (IQR 2-12) infusions. Of 48 patients, 11 had a third course with a median of 4 (IQR 2-9) infusions and one patient had a fourth course with four doses administered. The median time of discontinuation after the first course was 0.74 (IQR 0.43-1.09) years, after the second, 1.16 (IQR 0.54-1.73) years, and 1.02 years after the third. At the end of study, 78/250 (31.2%) patients were on infliximab treatment with a median of 25 (IQR 18-32) infusions, and of those, 59/78 (75.6%) patients were on their first course with a median of 11 infusions. The main reasons for discontinuing the first course of infliximab were remission in 75/191 (39.3%) patients, loss of response in 47/191 (24.6%) patients and non-response in 35/191 (18.3%) patients. Of those who discontinued the first infliximab course due to remission, significantly more patients (48/75; 64%) had concomitant treatment with a thiopurine compared with those who failed or developed intolerance to infliximab, 55/116 (47.4%) (P = 0.025).
Primary response and the subsequent risk of colectomy One hundred ninety patients (76.0%) had a response to induction treatment with infliximab at 3 months, which was associated with a decreased risk of colectomy at 12 months, compared with non-response (6/190 vs. 29/60; P < 0.0001) and at median follow-up of 2.9 (IQR 1.6-4.8) years (27/190 vs. 41/60; P < 0.0001) (Figure 1 ). Of the eight patients who previously received rescue treatment with infliximab, three were colectomized. Two of them had a primary non-response and one patient lost response after 14 infusions. Figure 2 .
Colectomy rate and predictors of colectomy The median age at colectomy was 32.8 years (IQR 24.9-45.5). Overall, the colectomy rate was 68/250 (27.2%) after a median follow-up of 2.9 years (IQR 1.6-4.7) as shown in Figure 3 . The median time to colectomy was 1.0 years (IQR 0.8-2.1). In total, 35/68 (51.5%) colectomies were performed within 12 months from initiation of infliximab treatment. Predictive factors for colectomy both at 12 months and at last follow-up were assessed. At 12 months, univariate analysis was significant for non-response at 3 months (OR = 28.7, 95% CI = 11.0-74.8, P < 0.001) and extensive disease (OR = 2.26, 95% CI = 1.03-4.93, P = 0.041). Only nonresponse at 3 months remained significant in the multivariate analysis (OR = 37.1, 95% CI = 10.8-128.1, P < 0.001) ( Table 2) . Using a Kaplan-Meier survival curve for remaining free of colectomy at last follow-up, a Cox proportional-hazards regression model was applied. Again, non-response at 3 months (HR = 8.6, 95% CI = 5.2-14.1, P < 0.001) and extensive disease, but also younger age at inclusion (<26 years) and the presence of primary sclerosing cholangitis were significant in the univariate analysis. However, in the multivariate analysis, only non-response at 3 months remained significant (HR = 9.4, 95% CI = 5.1-17.4, P < 0.001) (Table 3 ). Finally, we compared patients who were immunomodulator naive to patients who had failed immunomodulator therapy with added infliximab and patients with infliximab monotherapy who had failed immunomodulator in the past. No difference was detected concerning colectomy rate between the groups (data not shown). However, only 24 patients (9.6%) were naive to immunomodulators, and this number is probably too small to detect a significant difference. Figure 2 | Kaplan-Meier survival curve for remaining free of colectomy comparing responders (n = 181) with non-responders (n = 34) at 12 months after the first dose of infliximab. P-value obtained from log-rank test.
Predictors of primary response to infliximab at 3 months Predictors of initial response to infliximab treatment were assessed. Of the variables studied, two were significant in the univariate analysis: age >26 years (OR = 0.50 for age <26 years, 95% CI = 0.26-0.97, P = 0.040) and F-calprotectin >935 lg/g (OR = 11.7, 95% CI = 1.33-103.8, P = 0.027). None of the variables remained significant in the multivariate analysis (Table 4) .
Predictors of clinical response and remission at 12 months Among the 13 variables studied for at least response at 12 months, three were significant positive predictors in the univariate analysis: primary response at 3 months, age >26 years and F-calprotectin >935 lg/g. In the multivariate analysis, only primary response at 3 months remained significant (OR for non-response 0.023, 95% CI 0.008-0.065, P < 0.001) ( Table 5 ). The analysis was also made for clinical remission at 12 months. Primary response, concomitant 5-aminosalicylic acid treatment and F-calprotectin >935 lg/g were significant positive predictors in the univariate analysis. However, only primary response remained significant in the multivariate analysis (OR for non-response = 0.06, 95% CI = 0.02-0.17, P < 0.001) ( Table 6 ).
Safety and surgical complications
No deaths were observed. Altogether infliximab was discontinued in 31/250 (12.4%) patients due to adverse events, immediate infusion reactions being the most common. Acute infusion reactions occurred in 12/250 (4.8%) patients and one patient had a delayed hypersensitivity reaction, leading to infliximab discontinuation. Eight of the 12 acute infusion reactions occurred during the first course of infliximab. Three reactions occurred among 48 patients receiving a second course and one reaction occurred in 11 patients receiving a third course. All four reactions during the second or third infliximab course were preceded by a short first course (≤3 infusions) and occurred early after reintroduction. Only two of the 12 patients (17%) with infusion reactions had combination therapy with azathioprine. Five patients discontinued infliximab due to severe infections, including pyelonephritis, pneumonitis of unknown origin, legionella infection, miliary tuberculosis and herpes meningitis. Other reasons for discontinuation included single cases of myelitis, myelofibrosis, neuropathic pain, pulmonary embolism, lupus like syndrome, exanthema and psoriasis. In the colectomized patients, no major surgical complications were noted during the first month. Two of the 68 patients were colectomized due to dysplastic lesions. 
DISCUSSION
This study reports the hitherto largest real-life, longterm data of the efficacy and safety of infliximab in a defined cohort of patients with chronic active ulcerative colitis. Some studies report outcome in an acute severe attack of ulcerative colitis, 4, 8 but no previous real-life study has addressed chronic ulcerative colitis only. Most studies include various types of disease courses. 13, [16] [17] [18] In this study, we included patients with chronic active disease only and excluded hospitalised patients treated with infliximab as rescue therapy due to an acute severe attack of ulcerative colitis. The chronic type of ulcerative Logistic regression model showing outcome in univariate and multivariate analysis at 12 months after first infliximab infusion. Significance was set at 95% CI (P < 0.05). F-calprotectin and albumin were not retained in the multivariate analysis due to small numbers.
colitis population studied is further underscored by the fact that only four patients underwent colectomy within the first two months from initiation of infliximab, and almost all patients were treated or had previously been exposed to azathioprine/mercaptopurine at baseline.
Approximately one of four (24%) patients did not respond to infliximab at 3 months, which is similar to the non-response rate observed in the ACT studies, also comprising an ulcerative colitis population with chronic active disease. 5 The long-term benefit of infliximab in patients who responded to infliximab induction therapy Cox regression model showing outcome in univariate and multivariate analysis at time for observation (median 2.9 years). Significance was set at 95% CI (P < 0.05). F-calprotectin and albumin were not retained in the multivariate analysis due to small numbers.
is one of the main findings in our study. Three of four primary infliximab responders (143/190) had a long-term clinical benefit after a median time of 3.6 years. In addition, a similar number of patients had a clinical and steroid-free remission (123/250, 49.2%) at 12 months and long term (126/250, 50.4%) indicating the efficacy of infliximab over time. Others have found similar longterm outcomes of response but in smaller and more heterogeneous cohorts. 19, 20 Data are scarce regarding colectomy risk beyond 1 year in infliximab-treated patients. The long-term colectomy rate in our study was 27%. It is difficult to compare our observed colectomy rate with previous real-life reports, since most of them include heterogeneous patient Logistic regression model showing outcome in univariate and multivariate analysis at 3 months after initiation of infliximab treatment. Significance was set at 95% CI (P < 0.05). F-calprotectin and albumin were not retained in the multivariate analysis due to small numbers.
populations. A large single-centre study of 285 infliximabtreated patients with ulcerative colitis showed a colectomy rate of 20% after a follow-up of 5 years, 13 and a French large multi-centre study on 191 patients reported a colectomy rate of 19%. 16 Both these studies, however, like several others, did not separate patients with an acute severe attack from chronic ulcerative colitis. The strength of our data, except for the size, is that it is derived from a homogenous ulcerative colitis population with defined inclusion criteria. Studies on predictors of failure or response to anti-TNF therapy in ulcerative colitis show diverting results. Most studies include smaller cohorts, have limited follow-up and do not separate an acute severe attack from Logistic regression model showing outcome in univariate and multivariate analysis at 12 months after initiation of infliximab treatment. Significance was set at 95% CI (P < 0.05). F-calprotectin and albumin were not retained in the multivariate analysis due to small numbers.
a more chronic disease. From these studies, early clinical response seems to be the strongest predictor of a favourable course and lack of response to subsequent colectomy. 9, 17, [21] [22] [23] These findings were confirmed in our study. Primary non-response at 3 months was found to be a strong independent predictor of colectomy. Conversely, response at 3 months was associated with a low risk of colectomy of 3.2% at 12 months and predicted a continued response at 12 months and long term. Early mucosal healing, which is associated with clinical response, has also been shown to be a predictor of longterm response. 1, 23 Due to the retrospective design of the study, and the large number (15) of participating centres, we were not able to extract endoscopic data. Extensive Logistic regression model showing outcome in univariate and multivariate analysis at 12 months after initiation of infliximab treatment. Significance was set at 95% CI (P < 0.05). F-calprotectin and albumin were not retained in the multivariate analysis due to small numbers.
colitis has been shown to be a significant marker of poor outcome in previous studies. 22, 24 In our study, extensive colitis was a significant risk factor in the univariate analysis but did not remain significant in the multivariate analysis. However, disease extent measured at baseline may not reflect the actual disease extent at colectomy. In the ACT study, short disease duration (<2 years) increased the risk for colectomy 25 and others have shown that longer disease duration is a predictor of a more favourable outcome. 12 These observations were not confirmed in this study. However, younger age (<26 years) at infliximab treatment start was a significant predictor of colectomy in the univariate analysis but was not significant in the multivariate analysis. Combination treatment with infliximab and azathioprine was shown to be superior to either drug alone in the SUCCESS randomised trial, 11 and retrospective studies have shown a favourable outcome for combination therapy in thiopurine naive patients with a steroid-dependent ulcerative colitis both at 12 months and more long term. 9, 10 In this study, only 24 (9.6%) patients were immunomodulator naive and the majority of patients with infliximab monotherapy had previously failed thiopurine treatment. We were not able to demonstrate a reduced risk of colectomy in patients on co-treatment with azathioprine at the time of inclusion compared with infliximab alone. However, patients who discontinued their first infliximab course due to remission were significantly more likely to be on concomitant treatment with azathioprine compared with those who stopped due to failure, indicating some benefit of combination therapy. Laboratory biomarkers of inflammation (low haemoglobin or albumin and high Creactive protein) have been shown to be predictors of colectomy. 4, 16, 23, 26 These biomarkers were not demonstrated to be significant for outcome in our study, which may be explained by the fact that the patients represent a homogenous cohort of more chronic long-standing disease. The only laboratory finding predicting response at both 3 and 12 months was a high faecal calprotectin value (>935 lg/g), but the statistical significance of this was not retained in the multivariate model due to small sample size. However, an early drop in F-calprotectin has previously been shown to correlate to endoscopic remission. 27 Most of the infusion reactions (10/12) occurred in patients with infliximab monotherapy. Concomitant treatment with immunomodulators such as azathioprine, mercaptopurine and methotrexate has been shown to be protective against development of antibodies to infliximab and infusion reactions. 28, 29 In four patients, the infusion reactions occurred during the second or third course of infliximab treatment. These four patients received repeated short courses of infliximab, which has been shown to be highly immunogenic 30 and none of them had concomitant immunomodulator treatment. Our study has several limitations. Its retrospective nature can limit the validity of the data, due to selection bias. However, we consider this bias to be of minor importance. In university hospital IBD units, only a small minority are referrals and they almost exclusively serve their own primary uptake area. Given the large number of participating centres, with little referral bias, the results of this real-life study are close to reflect the outcome in a populationbased cohort. Second, data such as clinical response and remission were only based on clinician's assessment and not on disease activity indexes or objective markers of disease activity. Furthermore, data were captured mostly before the entry of drug monitoring and may not reflect current treatment. Given that fact, we were unable to find a time trend in colectomy rate during the period.
In summary, our study reports one of the largest and longest real-life experiences on the efficacy and safety of infliximab treatment in patients with chronic active ulcerative colitis and demonstrates an excellent long-term efficacy, particularly in patients with an early response to treatment.
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